|
|
||||
|
|
||||
|
||||
Can analysts provide better guidance to policymakers about the valuation of health effects? This paper argues that valuation questions usually cannot be easily sidestepped by the use of cost-effectiveness analysis. Valuations are implicit in the measures of program outcome that we use, as illustrated by an examination of a policy of maximizing discounted quality-adjusted life-years (QALYs). The paper concludes that surveys focused directly on the questions that health and safety policymakers face could be a most fruitful source of guidance.
This article has been cited by other articles:
![]() |
J. L. Puma Anticipated Changes in the Doctor-Patient Relationship in the Managed Care and Managed Competition of the Health Security Act of 1993 Arch Fam Med, August 1, 1994; 3(8): 665 - 671. [Abstract] [PDF] |
||||
|
|